GlassScriptPhysician profile
John R Atwell
NPI 1174504914
$5,699.26
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $311 · 2021: $554 · 2022: $1,287 · 2023: $2,550 · 2024: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810 · Travel and Lodging: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.19 |
| Travel and Lodging | $1,199.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $2,007.44 | 2022-2024 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $738.92 | 2019-2024 | Veozah, Myrbetriq |
| Teleflex LLC | $592.16 | 2022 | |
| Axonics, INC. | $579.48 | 2021-2024 | Axonics |
| Coloplast Corp | $368.20 | 2019-2022 | |
| Boston Scientific Corporation | $198.68 | 2019-2023 | Lithovue |
| Tolmar Pharmaceuticals, INC. | $162.04 | 2019-2022 | |
| Antares Pharma, INC. | $151.64 | 2021-2024 | Xyosted |
| Laborie Medical Technologies Corp. | $133.23 | 2023-2024 | Urgent PC Neuromodulation System |
| Halozyme INC | $63.51 | 2023 | |
| Blue Earth Diagnostics | $56.77 | 2023-2024 | |
| Allergan, INC. | $48.11 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $46.78 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $43.16 | 2020-2021 | |
| Urogen Pharma, INC. | $40.68 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $38.56 | 2023-2024 | |
| Myovant Sciences INC. | $34.05 | 2022 | |
| Rochester Medical Corporation | $33.23 | 2021 | |
| Sumitomo Pharma America, INC. | $32.40 | 2023 | Gemtesa |
| Urovant Sciences INC | $31.79 | 2022 | |
| Olympus America INC. | $31.77 | 2019-2024 | Bovie |
| Clarus Therapeutics INC. | $28.12 | 2021 | |
| Janssen Biotech, INC. | $27.65 | 2019 | |
| Abbvie INC. | $25.29 | 2023 | Botox |
| Pfizer INC. | $23.46 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $22.85 | 2020 | |
| Karl Storz Endoscopy-America | $22.70 | 2019 | |
| Agiliti Surgical, INC. | $21.72 | 2023 | Trinity |
| Ferring Pharmaceuticals INC. | $21.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.60 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.25 | 2021 | |
| Neotract INC. | $15.12 | 2020 | |
| Dendreon Pharmaceuticals LLC | $14.04 | 2019 | |
| Dentsply Ih INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Atwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.